Alloknesia (touch-triggered itching) in adults with atopic dermatitis
Study of Alloknesia in Atopic Dermatitis
University Hospital, Brest · NCT06923202
This study will see how common touch-triggered itching (alloknesia) is and how it affects adults with atopic dermatitis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 160 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Brest (other) |
| Locations | 8 sites (Angers and 7 other locations) |
| Trial ID | NCT06923202 on ClinicalTrials.gov |
What this trial studies
This observational study will enroll adults with atopic dermatitis diagnosed for at least six months to measure the frequency of alloknesia and its impact on daily life. Participants will complete standardized questionnaires and undergo a clinical examination at participating French hospitals to document symptoms and quality-of-life consequences. People on prolonged systemic treatment or unable to complete questionnaires are excluded. Collected data will be used to describe prevalence and burden of alloknesia across the study sites.
Who should consider this trial
Good fit: Adults (18 years and older) with a diagnosis of atopic dermatitis for more than six months who can complete questionnaires and are not on long-term systemic therapy are ideal candidates.
Not a fit: Children, patients currently receiving systemic treatments for a month or longer, those under legal protection, or anyone unable to complete questionnaires are unlikely to benefit from participating.
Why it matters
Potential benefit: If successful, the results could help clinicians recognize and address touch-triggered itching, leading to better symptom management and improved quality of life for affected patients.
How similar studies have performed: This is a novel effort because the epidemiology and burden of alloknesia in chronic itch have not been previously studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years * No opposition from the patient * Diagnosis of atopic dermatitis more than 6 months old Exclusion Criteria: * Patients who are physically or mentally unable to complete the questionnaires. * Patients on systemic treatment for 1 month or more * Refusal to participate * Patients under legal protection (guardianship, curatorship) * Patients under court protection
Where this trial is running
Angers and 7 other locations
- CHU d'Angers — Angers, France (NOT_YET_RECRUITING)
- CHU de Brest — Brest, France (RECRUITING)
- CHD Vendée — La Roche-sur-Yon, France (NOT_YET_RECRUITING)
- Groupe Hospitalier Bretagne Sud — Lorient, France (NOT_YET_RECRUITING)
- CHU de Nantes Hôtel-Dieu — Nantes, France (NOT_YET_RECRUITING)
- CHU de Rennes — Rennes, France (NOT_YET_RECRUITING)
- CHU de Tours — Tours, France (NOT_YET_RECRUITING)
- CH Bretagne Atlantique — Vannes, France (NOT_YET_RECRUITING)
Study contacts
- Study coordinator: Laurent MISERY, PUPH
- Email: laurent.misery@chu-brest.fr
- Phone: 02 98 22 33 15
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Atopic Dermatosis, Alloknesie